| Adaptive designs in clinical trials: why use them, and how to run and report them P Pallmann, AW Bedding, B Choodari-Oskooei, M Dimairo, L Flight, ... BMC medicine 16 (1), 1-15, 2018 | 149 | 2018 |
| Extended and standard duration weight-loss programme referrals for adults in primary care (WRAP): a randomised controlled trial AL Ahern, GM Wheeler, P Aveyard, EJ Boyland, JCG Halford, AP Mander, ... The Lancet 389 (10085), 2214-2225, 2017 | 111 | 2017 |
| Adaptive designs for dual-agent phase I dose-escalation studies JA Harrington, GM Wheeler, MJ Sweeting, AP Mander, DI Jodrell Nature Reviews Clinical Oncology 10 (5), 277, 2013 | 57 | 2013 |
| How to design a dose-finding study using the continual reassessment method GM Wheeler, AP Mander, A Bedding, K Brock, V Cornelius, AP Grieve, ... BMC medical research methodology 19 (1), 1-15, 2019 | 25 | 2019 |
| AplusB: A Web Application for Investigating A + B Designs for Phase I Cancer Clinical Trials G Wheeler, M Sweeting, A Mander PLoS ONE 11 (7), e0159026, 2016 | 12 | 2016 |
| Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials GM Wheeler, MJ Sweeting, AP Mander Statistics in Medicine 36 (16), 2499-2513, 2017 | 11 | 2017 |
| Incoherent dose-escalation in phase I trials using the escalation with overdose control approach G Wheeler Statistical Papers, 1-11, 2016 | 7 | 2016 |
| Modelling semi‐attributable toxicity in dual‐agent phase I trials with non‐concurrent drug administration GM Wheeler, MJ Sweeting, AP Mander, SM Lee, YKK Cheung Statistics in medicine 36 (2), 225-241, 2017 | 5 | 2017 |
| AUTO1, a novel fast off CD19CAR delivers durable remissions and prolonged CAR T cell persistence with low CRS or neurotoxicity in adult ALL C Roddie, MA O'Reilly, MAV Marzolini, L Wood, J Dias Alves Pinto, ... Blood, The Journal of the American Society of Hematology 134 (Supplement_1 …, 2019 | 4 | 2019 |
| MA12. 05 phase 1 study of HSP90 inhibitor ganetespib with pemetrexed and cisplatin/carboplatin chemotherapy for pleural mesothelioma D Fennell, S Danson, M Forster, D Talbot, P Woll, J Child, Y Ngai, ... Journal of Thoracic Oncology 13 (10), S397, 2018 | 3 | 2018 |
| The Lasso Logistic Regression Model: Modifications to aid causality assessment for Adverse Events Following Immunization G Wheeler London School of Hygiene and Tropical Medicine, 2010 | 3 | 2010 |
| A review of available software for adaptive clinical trial design MJ Grayling, GM Wheeler Clinical Trials 17 (3), 323-331, 2020 | 2 | 2020 |
| Nivolumab and ipilimumab treatment in prostate cancer with an immunogenic signature (NEPTUNES). YNS Wong, P Sankey, DH Josephs, RJ Jones, SJ Crabb, S Beare, ... Journal of Clinical Oncology 37 (15_suppl), TPS5090-TPS5090, 2019 | 2 | 2019 |
| A Bayesian model‐free approach to combination therapy phase I trials using censored time‐to‐toxicity data GM Wheeler, MJ Sweeting, AP Mander Journal of the Royal Statistical Society: Series C (Applied Statistics) 68 …, 2019 | 2 | 2019 |
| The effect of referral to an open‐group behavioural weight‐management programme on the relative risk of normoglycaemia, non‐diabetic hyperglycaemia and type 2 diabetes … AL Ahern, SJ Griffin, GM Wheeler, SJ Sharp, P Aveyard, EJ Boyland, ... Diabetes, Obesity and Metabolism 22 (11), 2069-2076, 2020 | 1 | 2020 |
| Ganetespib in Combination with Pemetrexed–Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial DA Fennell, S Danson, PJ Woll, M Forster, D Talbot, J Child, L Farrelly, ... Clinical Cancer Research 26 (18), 4748-4755, 2020 | 1 | 2020 |
| Designing and evaluating dose-escalation studies made easy: The MoDEsT web app P Pallmann, F Wan, AP Mander, GM Wheeler, C Yap, S Clive, ... Clinical Trials 17 (2), 147-156, 2020 | 1 | 2020 |
| Automated Manufacture of Matched Donor-Derived Allogeneic CD19 CAR T-Cells for Relapsed/Refractory B-ALL Following Allogeneic Stem Cell Transplantation: Toxicity, Efficacy and … C Roddie, MA O'Reilly, MAV Marzolini, L Wood, J Dias Alves Pinto, ... Blood, The Journal of the American Society of Hematology 134 (Supplement_1 …, 2019 | 1 | 2019 |
| TACTICAL: A phase I/II trial to assess the safety and efficacy of MSCTRAIL in the treatment of metastatic lung adenocarcinoma. A Davies, B Sage, K Kolluri, D Alrifai, R Graham, B Weil, R Rego, O Bain, ... Journal of Clinical Oncology 37 (15_suppl), TPS9116-TPS9116, 2019 | 1 | 2019 |
| EACH: A randomised phase II study evaluating the safety and anti-tumour activity of the combination of avelumab and cetuximab relative to avelumab monotherapy in recurrent … MD Forster, JJ Sacco, AH Kong, G Wheeler, S Forsyth, R Bhat, K Blair, ... Journal of Clinical Oncology 37 (15_suppl), TPS6091-TPS6091, 2019 | 1 | 2019 |
